Diaza-spiropiperidine derivatives
    1.
    发明申请
    Diaza-spiropiperidine derivatives 失效
    二氮杂 - 哌啶衍生物

    公开(公告)号:US20050154001A1

    公开(公告)日:2005-07-14

    申请号:US11028281

    申请日:2005-01-03

    IPC分类号: C07D471/10 A61K31/4747

    CPC分类号: C07D471/10

    摘要: The present invention relates to compounds of formula wherein A-B is —CH2—CH2—, —CH2—O— or —O—CH2—; X is hydrogen or hydroxy; R1 is aryl, optionally substituted by one or two substituents selected from the group consisting of halogen, lower alkyl, cyano, CF3, —OCF3, lower alkoxy, —SO2-lower alkyl and heteroaryl; R2 is aryl, optionally substituted by one or two substituents selected from the group consisting of halogen, lower alkyl, CF3, and lower alkoxy; R3 is hydrogen or lower alkyl; n is 0, 1 or 2; or a pharmaceutically active salt thereof. The compounds of the invention may be used in the treatment of neurological and neuropsychiatric disorders.

    摘要翻译: 本发明涉及下式的化合物其中AB是-CH 2 -CH 2 - , - CH 2 -O - 或-O- CH 2 - ; X是氢或羟基; R 1是芳基,任选被一个或两个选自卤素,低级烷基,氰基,CF 3,-OCF 3, 低级烷氧基,-SO 2 - 低级烷基和杂芳基; R 2是任选被一个或两个选自卤素,低级烷基,CF 3 N 3和低级烷氧基的取代基取代的芳基; R 3是氢或低级烷基; n为0,1或2; 或其药物活性盐。 本发明的化合物可用于治疗神经和神经精神障碍。

    Triaza-spiropiperidine derivatives
    2.
    发明申请
    Triaza-spiropiperidine derivatives 失效
    三氮杂 - 哌啶衍生物

    公开(公告)号:US20050107373A1

    公开(公告)日:2005-05-19

    申请号:US10967534

    申请日:2004-10-18

    CPC分类号: C07D471/10

    摘要: The invention relates to compounds of the general formula wherein A-A is —CH2—CH2—, —CH2—CH2—CH2—, —CH2—O— or —O—CH2—; and X, R1, R2, R3, R4, R5, R6, n, and p are as defined herein, or a pharmaceutically acceptable salt thereof for the treatment of psychoses, pain, neurodegenerative dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

    摘要翻译: 本发明涉及以下通式的化合物:其中AA是-CH 2 -CH 2 - , - CH 2 -CH 2 -CH 2 - , - CH 2 -O-O-或-O-CH 2 - ; - 和X,R 1,R 2,R 3,R 4,R 5, 本发明中,n和p如本文所定义,或其药学上可接受的盐用于治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆等疾病 哪些认知过程受损,如注意力缺陷障碍或阿尔茨海默病。

    IMIDAZOLE DERIVATIVES
    3.
    发明申请
    IMIDAZOLE DERIVATIVES 有权
    咪唑衍生物

    公开(公告)号:US20080103306A1

    公开(公告)日:2008-05-01

    申请号:US11955421

    申请日:2007-12-13

    IPC分类号: C07D401/04 C07D401/14

    CPC分类号: C07D401/06 C07D401/14

    摘要: The present invention relates to process for the preparation of an imidazole derivative of formula I, wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain.

    摘要翻译: 本发明涉及制备式I咪唑衍生物的方法,其中R 1,R 2,R 3和R 3, SUP> 4 如上所述。 这些化合物可用于治疗或预防mGluR5受体介导的疾病。 这些化合物尤其用于治疗或预防急性和/或慢性神经障碍,例如精神病,癫痫,精神分裂症,阿尔茨海默病,认知障碍和记忆缺陷以及慢性和急性疼痛。

    Imidazole derivatives
    5.
    发明申请
    Imidazole derivatives 失效
    咪唑衍生物

    公开(公告)号:US20050054686A1

    公开(公告)日:2005-03-10

    申请号:US10926670

    申请日:2004-08-26

    CPC分类号: C07D401/06 C07D401/14

    摘要: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3, R4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the imidazole derivatives of formula I, a process for preparing a compound of formula I, and a method of treating or preventing acute and/or chronic neurological disorder comprising administering to a patient in need of such treatment and/or prevention a therapeutically effective amount of said pharmaceutical composition. These disorders include Alzheimer's disease. These disorders also include mild cognitive impairment.

    摘要翻译: 本发明涉及式I的咪唑衍生物,其中R 1,R 2,R 3,R 4,X,Y和R如上所述,或其药学上可接受的盐。 本发明还涉及药物组合物,其包含式I的咪唑衍生物,制备式I化合物的方法,以及治疗或预防急性和/或慢性神经障碍的方法,包括对需要这种治疗的患者施用 和/或预防治疗有效量的所述药物组合物。 这些疾病包括阿尔茨海默氏病。 这些疾病也包括轻度认知障碍。

    Diazole derivatives
    8.
    发明申请
    Diazole derivatives 审中-公开
    二唑衍生物

    公开(公告)号:US20060030559A1

    公开(公告)日:2006-02-09

    申请号:US11141547

    申请日:2005-05-31

    CPC分类号: C07D401/06 C07D401/14

    摘要: The present invention relates to diazole derivatives of the general formula wherein A, E, R1, R2 and R3 are as defined in application and pharmaceutical compositions containing them. The invention also relates to use of such compounds for the treatment of diseases mediated by the metabotropic glutamate receptors (mGluR), such as anxiety, chronic and acute pain, protection against liver damage, urinary incontinence, obesity, Fragile-X and autism, Alzheimer's disease, epilepsy, schizophrenia, ischemia, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDs, and Parkinson's disease.

    摘要翻译: 本发明涉及以下通式的二唑衍生物:其中A,E,R 1,R 2和R 3如申请中所定义 和含有它们的药物组合物。 本发明还涉及这种化合物用于治疗由代谢型谷氨酸受体(mGluR)介导的疾病的用途,例如焦虑,慢性和急性疼痛,防止肝损伤,尿失禁,肥胖,脆性-X和自闭症,阿尔茨海默病 疾病,癫痫,精神分裂症,局部缺血,亨廷顿舞蹈病,肌萎缩性侧索硬化(ALS),AID引起的痴呆和帕金森病。

    Imidazole derivatives
    9.
    发明申请
    Imidazole derivatives 有权
    咪唑衍生物

    公开(公告)号:US20050009878A1

    公开(公告)日:2005-01-13

    申请号:US10874948

    申请日:2004-06-23

    摘要: The present invention relates to imidazole derivatives of the general formula wherein R1, R2, R3 and R4 are as defined hereinabove. This invention also relates to the compound's pharmaceutically acceptable salt and processes for the preparation thereof. These compounds can be used for the manufacture of pharmaceutical compositions for the treatment and prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficit disorders, as well as chronic and acute pain.

    摘要翻译: 本发明涉及以下通式的咪唑衍生物:其中R 1,R 2,R 3和R 4如上所定义。 本发明还涉及该化合物的药学上可接受的盐及其制备方法。 这些化合物可用于制备用于治疗和预防mGluR5受体介导的病症的药物组合物。 这些化合物尤其用于治疗或预防急性和/或慢性神经障碍如精神病,癫痫,精神分裂症,阿尔茨海默病,认知障碍和记忆缺陷障碍以及慢性和急性疼痛。